Take a global view of myasthenia gravis management. Compare evolving guideline recommendations, uncover practical clinical applications ... Show more
Autoimmune Disorders
Story Details
| Last Updated | |
| Total Articles | 2 |
Main Topics
postgraduate academic degree awarded by most universities worldwide
News on this topic
Take a global view of myasthenia gravis management. Compare evolving guideline recommendations, uncover practical clinical applications ... Show more
Autoimmune Disorders
Autoimmune Disorders
Similar to This
Previous
Autoimmune Disorders: Is it time to switch? Learn to align therapeutic choices with individual patient characteristics to achieve truly patient-centric outcomes.
medscape.org/advances/neuromuscular-disorders-myasthenia-gravis-chronic-2026a1000cjv
Optimizing Clinical Practice in Prostate Cancer: Keep up to date on the latest data in advanced prostate cancer and gain expert insights on their implications ...
medscape.org/advances/optimizing-clinical-practice-prostate-cancer-2026a1000jj9
Neurological and Psychiatric Disorders: Expand your knowledge and understanding of epilepsy and brain health.
medscape.org/advances/neuro-psych-2026a1000htp
Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln: Italian pharma group Recordati said on Friday it would buy from Sanofi the global ...
reut.rs/3zAn6IB
Key FactsRecordati Acquires Rights to Rare CAD Drug
Oct 4, 2024 · Reading time: ~30 sec.
Summary created with AI assistance · Source: reuters.com
Summary created with AI assistance · Source: reuters.com
- Recordati is purchasing global rights to Enjaymo from Sanofi, a biologic approved by the FDA for treating cold agglutinin disease, a rare autoimmune disorder.
- The agreement includes potential commercial milestone payments up to $250 million, pending regulatory approval for completion by the end of 2024.
- Funding will come from existing cash reserves and new bank debt, with expected net debt ratios of 2.4-2.5 times EBITDA in 2024 and 2.0 times in 2025.
- Share prices for both Recordati and Sanofi increased following the announcement of the transaction.
Next